Syndax

Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
Second-quarter catalysts for the smaller players
EP Vantage
Wed, 04/7/21 - 10:25 am
AC Immune
Anavex
Santhera
IMMUTEP
Syndax
Novan
Fulcrum Therapeutics
BeyondSpring
Corbus
Orphazyme
Aldeyra
Adaptimmune
Inflarx
Sutro
Gemini Therapeutics
Briggs Morrison’s little biotech Syndax concedes 2 key trial setbacks for its lead drug, as shares shrivel some more
Endpoints
Thu, 03/7/19 - 09:43 pm
Syndax
Briggs Morrison
clinical trials
entinostat
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
Mon, 05/28/18 - 02:14 pm
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
5 biotech CEOs on payers, investors and big bets
BioPharma Dive
Fri, 03/10/17 - 09:42 am
biotech
payers
investors
Gil Van Bokkelen
Athersys
Robert McNeil
DalCor Pharmaceuticals
Pierre Belichard
Enterome
Michael Metzger
Syndax
Spiro Rombotis
Cyclacel
Here are 13 MA cancer biotechs hoping to make waves next month
Bizjournals.com
Fri, 05/20/16 - 11:36 am
Boston
biotech
ASCO 2016
Ariad Pharmaceuticals
Immunogen
Ziopharm
Vertex Pharmaceuticals
Tokai
Infinity Pharmaceuticals
Momenta
Merrimack
Tesaro
Syndax
Kyropharm
Foundation Medicine
Cerulean Pharma
AstraZeneca R&D executive Morrison to lead cancer firm Syndax
Yahoo/Reuters
Mon, 06/15/15 - 09:28 am
AstraZeneca
R&D
cancer
Briggs Morrison
Syndax